Loading...
Market
Which countries will approve LSCD treatment using iPSCs by end of 2025?
2
Resolution / Starting Odds
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
Regulatory announcements from respective countries
Story
Osaka University Researchers Restore Vision in Four Patients with Limbal Stem Cell Deficiency Using Stem Cells
Nov 9, 2024, 02:36 PM
Researchers from Osaka University have achieved a significant breakthrough in treating blindness caused by limbal stem cell deficiency (LSCD) using induced pluripotent stem cells (iPSCs). In a first-of-its-kind interventional study conducted in Japan, the team performed corneal transplant surgery on four patients, with promising results. The study, which was a single-arm, open-label trial, demonstrated rapid vision improvement in all patients post-transplant, with their improved vision remaining stable over time. Notably, only one patient experienced a decline in vision during the initial year following the procedure. This innovative approach marks a pivotal advancement in regenerative medicine and offers new hope for individuals suffering from LSCD.
View original story
Similar markets
0 countries • 25%
1-2 countries • 25%
3-4 countries • 25%
5 or more countries • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
Parkinson's Disease • 25%
Heart Disease • 25%
Spinal Cord Injury • 25%
Other • 25%
Yes • 50%
No • 50%
United States • 25%
China • 25%
European Union • 25%
Other • 25%
0 companies • 25%
1-2 companies • 25%
3-4 companies • 25%
5 or more companies • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
Germany • 25%
Japan • 25%
Other • 25%